Claim 1: a fatty acid derivative represented by formula (1) is used, wherein L, m and N are hydrogen, hydrogen Xi, halogen, low hydrocarbon group and hydrogen oxygen group (below),Low end alkoxy or oxo, in which the five members of the ring have at least one double link； a es-ch3 o-ch2oh, coh2oh or one of its functional derivatives； B is a simple link, ch2-ch2 -.-CH=CH---C...-CH2-CH2-CH2-CH=CH-CH2---CH2-CH=CH---CºC-CH2- or -CH2-CºC-；Z is a part selected from (2) formula group or single bond group, wherein R4 and R5 are hydrogen, hydrogen Xi, halogen, low tar, low oxygen or hydrogen peroxide (lower),R4 and R5 are not the same hydrogen Xi and alcoxi； Z1 and Z2 are oxygen, nitrogen or sulfur； R6 and R7 are selectively combined to form a lower tar layer to be replaced； R1 is an oxidized water residue less than or equal to saturation or unsaturation, not replaced or Alternatives are halogens, low tar, hydrogen Xi, oxo, arilo or heterocyclic compounds, and carbon atoms in at least one propylene hydrocarbon, optionally oxygen, nitrogen or sulfur； RA is a low degree or semi saturated or unsaturated carbonate residue,Not replaced or replaced by halogen, oxo, hydroxi, low hydrocarbon, low oxygen, low oxygen, low oxygen and cyclopentyl,CYCLOPROPYLENE glycol (Times)Arilo, ariloxi, heterocyclic or isoepoxy group； alcoxi low； alcoil low oxygen； cycloquilo (low)；1. Cyclopropylucci (Times)；aryl； aryloxy； heterocyclic group； heterocyclic-oxy group and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted with oxygen, nitrogen or sulfur； for the preparation of a medicament for treating schizophrenia in a mammalian subject in need. Claim 6: Use according to claim 1, wherein the fatty acid derivative is (-) - 7 - [(1R, 2R) - 2- (4,4-Difluoro-3-oxooctyl) -5-oxocyclopentyl] heptanoic, (Z) -7 - [(1R, 2R, 3R, 5S) -3,5-dihydroxy-2- (3-oxodecyl) (+) - isopropyl cyclopentyl] hept-5-enoate or (E) -7 - [(1R, 2R) -2- (4,4-difluoro-3-oxooctyl) -5-oxocycloperityl) hept 2
